CASI Pharmaceuticals, Inc. (CASI) Form 6-K — Jun 29, 2026
CASI Pharmaceuticals announced it has entered into a Settlement Agreement with Acrotech Biopharma Inc. to resolve an arbitration proceeding regarding the License Agreement for Evomela in China. Under the terms of the settlement, the prior termination of the License Agreement is rescinded, and the agreement will remain in full force and effect, subject to revisions including minimum purchase obligations.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.